Search

Your search keyword '"Libor Havel"' showing total 13 results
Start Over Author "Libor Havel" Journal lung cancer
Sorry, I don't understand your search. ×
13 results on '"Libor Havel"'

1. Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the 'good responder'?

Author

Martin Svaton, Michal Hrnčiarik, Leona Koubková, Jana Skrickova, Monika Bratová, Daniel Dolezal, Jana Krejčí, Libor Havel, Martin Safanda, Helena Čoupková, Magda Barinova, Marketa Cernovska, Juraj Kultan, Kristián Brat, Ondrej Fischer, Tana Tuzova, Milada Zemanova, Karolina Hurdalkova, and Miloš Pešek

Subjects
Oncology, medicine.medical_specialty, Prognostic factor, Lung, business.industry, medicine.disease, First line treatment, medicine.anatomical_structure, Treatment success, Internal medicine, medicine, Adenocarcinoma, Progression-free survival, business
Published
2021

2. Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry

Author

Libor Havel, Ondřej Venclíček, Marketa Cernovska, Helena Čoupková, M. Bařinová, Dan Krejčí, Jaromír Roubec, Zdeněk Merta, Ondřej Fišer, Monika Bratová, Leona Koubková, Andrea Benejová, Vítězslav Kolek, Milada Zemanova, P. Opálka, Michal Hrnčiarik, Jana Skřičková, Miloš Pešek, Martin Svatoň, Petra Májková, and Jana Krejčí

Subjects
biology, business.industry, Cancer research, biology.protein, Prospective data, Medicine, Epidermal growth factor receptor, business, EGFR Gene Mutation, Tyrosine kinase
Published
2020

3. Non-small Cell Lung Cancer as a chronic disease – a prospective study from the Czech TULUNG registry

Author

Vitezslav Kolek, Kristián Brat, Leona Koubková, Jana Krejčí, Bara Karlinova, Miloš Pešek, Libor Havel, Jana Skrickova, Michal Hrnčiarik, and Monika Šatánková

Subjects
Czech, Oncology, medicine.medical_specialty, business.industry, medicine.disease, language.human_language, Chronic disease, Internal medicine, medicine, language, Non small cell, Lung cancer, Prospective cohort study, business
Published
2019

4. Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic

Author

František Salajka, J. Krejčí, Andrea Benejová, P. Opálka, Jaromír Roubec, Helena Čoupková, Karel Hejduk, Milada Zemanova, Ladislav Dušek, Vítězslav Kolek, Monika Šatánková, Leona Koubková, Michal Hrnčiarik, Ivona Grygárková, Marcela Tomíšková, Jana Skřičková, Miloš Pešek, Petr Brabec, Zbyněk Bortlíček, Marketa Cernovska, Libor Havel, and Renata Chloupková

Subjects
Oncology, 0303 health sciences, medicine.medical_specialty, biology, business.industry, Afatinib, non-small cell lung cancer (NSCLC), medicine.disease, respiratory tract diseases, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Gefitinib, 030220 oncology & carcinogenesis, Internal medicine, medicine, biology.protein, Adenocarcinoma, Erlotinib, Epidermal growth factor receptor, business, Adverse effect, Tyrosine kinase, 030304 developmental biology, medicine.drug
Abstract

Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: Only patients with EGFR mutation and in which 1st line treatment started in October 2013 until October 2017 were included in analysis. We analysed 347 patients (gefitinib - 164 patients, afatinib - 130 patients, erlotinib - 53 patients). Results: Between these three groups of patients there was no statistically significant difference in sex (p=0.988), in smoking habits (p=0.549), in type of EGFR mutation (p=0.200), in adenocarcinoma proportion (p=0.256). There was statistically significant difference according to age (p=0.001), PS ( Conclusion: We have not found any important difference in basic characteristic of patients treated in 1st line treatment with TKI (sex, smoking, histology and type of EGFR mutation) except for the age – patients treated with afatinib were younger. We have not found any important difference in response to treatment, in disease control and OS. We found a significant difference in PS segmentation, in occurrence of adverse events and PFS.

Published
2018

5. Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic

Author

František Salajka, Libor Havel, Renata Chloupková, Leona Koubková, Jana Krejčí, Zdeněk Merta, Marketa Cernovska, Vítězslav Kolek, Andrea Benejová, Monika Šatánková, Dimka Sixtová, Milada Zemanova, Jaromír Roubec, Jana Skřičková, Miloš Pešek, Marcela Tomíšková, Michal Hrnčiarik, Karel Hejduk, and Ivona Grygárková

Subjects
Czech, Oncology, medicine.medical_specialty, biology, business.industry, Afatinib, Real life data, language.human_language, respiratory tract diseases, Exact test, Gefitinib, Internal medicine, Statistical significance, medicine, biology.protein, language, Epidermal growth factor receptor, business, Tyrosine kinase, medicine.drug
Abstract

Background and Aim: From October 2013 there is a possibility to treat patients with NSCLC and with activated epidermal growth factor receptor (EGFR) mutations with three TKI (afatinib, eriotinib, gefitinib) in the Czech Republic. We have tried to find differences among patient groups treated with single TKI in 1st line of treatment. Patients and methods: As data source we used the TULUNG registry, which is focused on the data collection of patients with NSCLC treated with target therapy in the Czech Republic. We analysed 232 patients (gefitinib - 115 patients, afatinib - 77 patients, eriotinib - 40 patients.). Statistical significance was assessed using the Fisher's exact test or Kruskal-Wallis test (a=0.05).

Published
2017

6. P-294 Interactions of lung cancer risk factors in women

Author

Petr Zatloukal, Libor Havel, A Kubík, Evzen Krepela, Norbert Pauk, and L Tomasek

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Epidemiology of cancer, medicine, Lung cancer, medicine.disease, business
Published
2005

7. O-262 Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomized phase II study — long-term follow-up data

Author

Petr Zatloukal, Lubos Petruzelka, Milada Zemanova, Libor Havel, Libor Judas, and Ladislav Pecen

Subjects
Pulmonary and Respiratory Medicine, Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Long term follow up, Locally advanced, Phases of clinical research, Vinorelbine, medicine.disease, Internal medicine, Medicine, Non small cell, business, Lung cancer, medicine.drug
Published
2003

9. Evaluation of radiation pneumotoxicity in patients with locally advanced non-small cell lung cancer (NSCLC) treated by concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P)

Author

Petr Zatloukal, A Bortlova, Milada Zemanova, Lubos Petruzelka, Libor Havel, and Jiří Homolka

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cisplatin, Cancer Research, medicine.medical_specialty, business.industry, Locally advanced, non-small cell lung cancer (NSCLC), medicine.disease, Vinorelbine, Internal medicine, medicine, In patient, business, medicine.drug
Published
2000

11. Lung cancer (LC) among women: Trends, risk factors, prevention

Author

Sara Gandini, Lubos Petruzelka, Nigel Gray, Chris Robertson, Libor Havel, Peter Boyle, A Kubík, Petr Zatloukal, and L Tomasek

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Medicine, business, Lung cancer, medicine.disease, Preventive healthcare
Published
2000

13. Vinorelbine plus cisplatin and concurrent radiotherapy in non-small cell lung cancer

Author

Petr Zatloukal, F Krejbich, Milada Zemanova, Luboš Petruželka, and Libor Havel

Subjects
Pulmonary and Respiratory Medicine, Oncology, Cisplatin, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Vinorelbine, medicine.disease, Radiation therapy, Internal medicine, medicine, Non small cell, business, Lung cancer, medicine.drug
Published
1998

Catalog

Books, media, physical & digital resources
See catalog results